<DOC>
	<DOC>NCT02675439</DOC>
	<brief_summary>The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) administered via intratumoral injection.</brief_summary>
	<brief_title>Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>ECOG â‰¤ 1 Willing to undergo tumor biopsies from injected and distal lesions Must have two biopsy accessible lesions: * one lesion must be 10 mm and &lt;100 mm in longest diameter, accessible for repeated intratumoral (IT) injection and accessible for baseline and ontreatment biopsies. a second (distal) lesion must be accessible for baseline and ontreatment biopsy and must be distinct from the injected lesion. tumors encasing major vascular structures (i.e., carotid artery or tumors close to other vital organs), are not considered appropriate Patients who require local palliative measures such as XRT or surgery Symptomatic or untreated leptomeningeal disease. Presence of symptomatic central nervous system (CNS) metastases Impaired cardiac function or clinically significant cardiac disease Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy. Active infection requiring systemic antibiotic therapy. Known history of Human Immunodeficiency Virus (HIV) infection. Active EpsteinBarr virus (EBV), HBV (hepatitis B virus) or HCV (hepatitis C virus) Malignant disease, other than that being treated in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>